Abstract
Oncogenic mutations activate secretory programs that drive tumor progression and represent therapeutic targets. The clinical relevance of CASPs is underscored by their prevalence, their linkages to specific genetic and epigenetic contexts, the proven efficacy of secretory blockade in preclinical models, and the availability of assays to identify vulnerable patient populations.
Document Type
Article
Publication Date
2024
Digital Object Identifier (DOI)
https://doi.org/10.1172/JCI182652
Funding Information
This work was supported in part by grants from the NIH (R01CA236781 and R01CA255021-01 to JMK and 5R03CA280382-03 to XT). JMK holds the Gloria Lupton Tennison Distinguished Professorship in Lung Cancer.
Repository Citation
Tan, Xiaochao; Xiao, Guan-Yu; Banerjee, Priyam; Wang, Shike; and Kurie, Jonathan M., "The cancer-associated secretory phenotype: a new frontier in targeted therapeutics" (2024). Markey Cancer Center Faculty Publications. 243.
https://uknowledge.uky.edu/markey_facpub/243
Notes/Citation Information
© 2024, Tan et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.